CN111465616B - 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途 - Google Patents

特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途 Download PDF

Info

Publication number
CN111465616B
CN111465616B CN201880079137.7A CN201880079137A CN111465616B CN 111465616 B CN111465616 B CN 111465616B CN 201880079137 A CN201880079137 A CN 201880079137A CN 111465616 B CN111465616 B CN 111465616B
Authority
CN
China
Prior art keywords
sequence
gly
ser
leu
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880079137.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111465616A (zh
Inventor
李种瑞
金奎兑
高凤国
金起贤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbClon Inc
Original Assignee
AbClon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbClon Inc filed Critical AbClon Inc
Publication of CN111465616A publication Critical patent/CN111465616A/zh
Application granted granted Critical
Publication of CN111465616B publication Critical patent/CN111465616B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880079137.7A 2017-12-06 2018-12-06 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途 Active CN111465616B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2017-0166969 2017-12-06
KR20170166969 2017-12-06
PCT/KR2018/015445 WO2019112347A2 (ko) 2017-12-06 2018-12-06 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도

Publications (2)

Publication Number Publication Date
CN111465616A CN111465616A (zh) 2020-07-28
CN111465616B true CN111465616B (zh) 2023-08-01

Family

ID=66749962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880079137.7A Active CN111465616B (zh) 2017-12-06 2018-12-06 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途

Country Status (8)

Country Link
US (2) US11534462B2 (https=)
EP (1) EP3722313A4 (https=)
JP (1) JP7089806B2 (https=)
KR (1) KR102136063B1 (https=)
CN (1) CN111465616B (https=)
AU (1) AU2018379502B2 (https=)
CA (1) CA3083936C (https=)
WO (1) WO2019112347A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210079111A1 (en) * 2018-08-04 2021-03-18 AbCyte Therapeutics Inc. Cd19-cd20 bispecific and dual passway car-t and methods for use thereof
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
CN112759651B (zh) * 2019-11-01 2022-09-20 北京华夏清医治疗科技有限公司 一种包含嵌合抗原受体修饰的t细胞及其应用
CN111909277A (zh) * 2020-08-13 2020-11-10 上海市第一人民医院 一种靶向trbc1的人源化嵌合抗原受体、t细胞及用途
KR102393776B1 (ko) * 2020-12-30 2022-05-04 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
WO2022234158A1 (es) * 2021-05-06 2022-11-10 Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) Terapia de células t con receptor de antígeno quimérico específico de cd19
US20230399375A1 (en) 2022-04-15 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
WO2023240064A1 (en) 2022-06-08 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
CN118359729A (zh) * 2023-01-19 2024-07-19 武汉昭智生物技术有限公司 一种car分子、包含其的细胞或外泌体及它们的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679492B2 (en) * 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
WO2016139487A1 (en) * 2015-03-05 2016-09-09 Ucl Business Plc Chimeric antigen receptor (car) comprising a cd19-binding domain
CN106554414A (zh) * 2015-09-18 2017-04-05 科济生物医药（上海）有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
WO2017066136A2 (en) * 2015-10-13 2017-04-20 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof
KR20170057298A (ko) * 2014-08-28 2017-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Cd19에 특이적인 항체 및 키메라 항원 수용체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US7169894B2 (en) * 2001-11-14 2007-01-30 Mirari Biosciences, Inc. Methods and compositions for reverse translation
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
JP2008546647A (ja) 2005-06-08 2008-12-25 デューク ユニバーシティ 移植のための抗−ｃｄ１９抗体治療
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
US9074002B2 (en) 2009-04-27 2015-07-07 Cold Spring Harbor Laboratory PTP1B inhibitors
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
GB2527285B (en) 2014-06-11 2021-05-26 Advanced Risc Mach Ltd Resource access control using a validation token

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679492B2 (en) * 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
KR20170057298A (ko) * 2014-08-28 2017-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Cd19에 특이적인 항체 및 키메라 항원 수용체
WO2016139487A1 (en) * 2015-03-05 2016-09-09 Ucl Business Plc Chimeric antigen receptor (car) comprising a cd19-binding domain
CN107406517A (zh) * 2015-03-05 2017-11-28 Ucl商务股份有限公司 包含cd19结合域的嵌合抗原受体(car)
CN106554414A (zh) * 2015-09-18 2017-04-05 科济生物医药（上海）有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
WO2017066136A2 (en) * 2015-10-13 2017-04-20 Eureka Therapeutics, Inc. Antibody agents specific for human cd19 and uses thereof

Also Published As

Publication number Publication date
CA3083936A1 (en) 2019-06-13
WO2019112347A2 (ko) 2019-06-13
US11534462B2 (en) 2022-12-27
US20230099646A1 (en) 2023-03-30
US20200384023A1 (en) 2020-12-10
JP7089806B2 (ja) 2022-06-23
WO2019112347A3 (ko) 2019-08-01
KR20190067125A (ko) 2019-06-14
AU2018379502A1 (en) 2020-06-18
AU2018379502B2 (en) 2025-07-17
EP3722313A4 (en) 2021-02-24
CN111465616A (zh) 2020-07-28
JP2021505137A (ja) 2021-02-18
CA3083936C (en) 2022-08-23
EP3722313A2 (en) 2020-10-14
KR102136063B1 (ko) 2020-07-22
US12090171B2 (en) 2024-09-17

Similar Documents

Publication Publication Date Title
CN111465616B (zh) 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
CN113234174B (zh) 靶向bcma的嵌合抗原受体及其使用方法
CN108373504B (zh) Cd24特异性抗体和抗cd24-car-t细胞
US11970547B2 (en) Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR20220006085A (ko) 클라우딘(Claudin) 18.2를 표적화하는 항체 또는 키메라 항원 수용체
CN111655732A (zh) 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体
KR20250107971A (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
CN109970859B (zh) Glypican-3特异性抗体及其特异性CAR-T细胞
CN115916823A (zh) 人cd45rc特异的嵌合抗原受体及其用途
EP4238990A1 (en) Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof
CN116249559A (zh) 抗独特型组合物及其使用方法
JP2024516308A5 (https=)
CN111542541B (zh) 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
TWI888376B (zh) 辨識抗體改變部位之嵌合受體
HK40025112B (zh) 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
HK40025112A (en) Antibody or antigen binding fragment thereof for specifically recognizing b cell malignancy, chimeric antigen receptor comprising same, and use thereof
HK40025710A (en) Antibody or antigen-binding fragment thereof that specifically recognizes b cell malignancies, chimeric antigen receptor comprising same, and uses thereof
HK40088437B (zh) 抗cd70纳米抗体及其用途
HK40088437A (zh) 抗cd70纳米抗体及其用途
WO2023246574A1 (zh) 靶向gpc3的抗体及其用途
WO2024094159A1 (zh) 靶向人源ror1的单域抗体
HK40075690A (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025112

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant